Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 51 min ago
Peer-reviewedLicence not statedJAMA

Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations

4 more authors
11 affiliations
  1. 1The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
  2. 2The George Institute for Global Health, New Delhi, India
  3. 3Improving Health Outcomes, American Medical Association, Greenville, South Carolina
  4. 4School of Population Health, University of New South Wales, Sydney, New South Wales, Australia
  5. 5The George Institute for Global Health, London, United Kingdom
  6. 6Departments of Cardiology, Nephrology, and Transplantation, Royal Perth Hospital, Perth, Western Australia, Australia
  7. 7Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit, Perth, Western Australia, Australia
  8. 8Deep Medicine, Nuffield Department of Women’s & Reproductive Health, University of Oxford, Oxford, United Kingdom
  9. 9Department of Epidemiology, Celia Scott Weatherhead School of Public Health & Tropical Medicine, Tulane University, New Orleans, Louisiana
  10. 10School of Medicine, Imperial College London, United Kingdom
  11. 11Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India

Related

  1. Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants
    R. Dhurjati, R. Pant, A. Kumar +20
    medRxivPreprintCC BYFull textCardiovascular medicinemedRxiv
  2. History of gastrointestinal symptoms with other glucose‐lowering agents is associated with gastrointestinal adverse events after imeglimin initiation: A retrospective real‐world study
    Kodai Yoshida, Yukiko Onishi, Tetsuya Kubota +7
    Journal of diabetes investigationPeer-reviewedCC BY-NCFull textEndocrinology & metabolismEurope PMC
  3. Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events
    Hope S. Rugo, David W. Cescon, Peter Schmid +18
    npj Breast CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Disciform Keratitis That Improves With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor Treatment for Ovarian Cancer but Recurs Upon Discontinuation of Treatment
    Atsuki Fukushima, Shintaro Kohno, Hitoshi Tabuchi
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Patient-Reported Tolerability, Treatment Initiation, and Discontinuation of Postoperative Progestin Therapy After Cesarean Scar Repair in Women Planning Pregnancy
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{wang2026adverse,
  title = {{Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations}},
  author = {Nelson Wang and Stephen van der Hoorn and Rashmi Pant and Amit Kumar and Rupasvi Dhurjatic and Faraidoon Haghdoost and Christian Abhayaratna and Brent M. Egan and Aletta Elisabeth Schutte and Otavio Berwanger and Anushka A Patel and Markus P. Schlaich and Kazem Rahimi and Paul Kieran Whelton and Anthony Rodgers and Abdul Salam},
  journal = {JAMA},
  year = {2026},
  month = may,
  doi = {10.1001/jama.2026.6214},
  url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13220152/},
}
RIS
TY  - JOUR
TI  - Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations
AU  - Nelson Wang
AU  - Stephen van der Hoorn
AU  - Rashmi Pant
AU  - Amit Kumar
AU  - Rupasvi Dhurjatic
AU  - Faraidoon Haghdoost
AU  - Christian Abhayaratna
AU  - Brent M. Egan
AU  - Aletta Elisabeth Schutte
AU  - Otavio Berwanger
AU  - Anushka A Patel
AU  - Markus P. Schlaich
AU  - Kazem Rahimi
AU  - Paul Kieran Whelton
AU  - Anthony Rodgers
AU  - Abdul Salam
PY  - 2026
DA  - 2026/05/28
JO  - JAMA
DO  - 10.1001/jama.2026.6214
UR  - https://pmc.ncbi.nlm.nih.gov/articles/PMC13220152/
SN  - 0002-9955
SN  - 0098-7484
SN  - 1538-3598
SN  - 2376-8118
ER  -